The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer

摘要: Lung cancer is the leading cause of death in United States and many other parts world. Non-small cell lung (NSCLC) comprises 85-90% cancers. Historically, expected survival patients with advanced disease has been estimated months. In recent years, however, come to be seen as a treatable multiple therapeutic options. Enormous advances understanding its pathways mechanisms have enabled personalized therapy NSCLC. The evolving approach focuses on genomic profiling tumors find molecular targets develop specific agents for individualized therapy. addition, maintenance emerged valid approach, choice chemotherapy now varies by histology. Most recently, immunotherapy checkpoint inhibitors shown promising results, impressive durations response tolerable toxicity profile. Together, these discoveries improved overall substantially patient populations that access advancements. We review clinical data surrounding improvements.